Related Experiment Video
Updated: Mar 30, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
[Progress in Examination and Treatment of Hepatitis C Virus]
Abstract:
Hepatitis C virus (HCV) is one of the major pathogens causing liver cirrhosis and hepatocellular carcinoma. For a long time, standard therapy against HCV infection involved a combination of pegylated interferon (PEG-IFN) and ribavirin (RBV). However, the sustained virological response (SVR) rate with this therapy can be up to 50%. Therefore, to predict the interferon response prior to treatment, novel viral and host factors were explored, and several novel examinations were developed. Recently, several classes of novel direct-acting antivirals (DAAs) targeting protease, NS5A, and polymerase of HCV have been developed and tested in clinical trials. HCV protease inhibitors, simeprevir and telaprevir, have been approved for the treatment of genotype 1 HCV infection in Japan. Moreover, recently, IFN-free regimens, the NS5A inhibitor Daclatasvir, and protease inhibitor Asunaprevir combination therapy have been approved in Japan. Treatment outcomes have been improved; however, viral resistance against DAAs has become a new issue. The aim of this review was to summarize the progress in examination and treatment of hepatitis C virus.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Related Concept Videos
Hepatitis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Chronic Pancreatitis II: Collaborative Care
Assessment:
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...